Q1 2025 Management View CEO William Feehery highlighted that Certara achieved $106 million in revenue for Q1 2025, ...

Certara, Inc. (NASDAQ:CERT), a leader in biosimulation and drug development, is making waves in the market with its growing ...

Q1 2025 Earnings Call Transcript May 5, 2025 Certara, Inc. beats earnings expectations. Reported EPS is $0.14, expectations ...

Certara Inc (CERT) reports a robust 10% revenue growth and unveils strategic advancements, while navigating industry ...

The projected fair value for Certara is US$8.98 based on 2 Stage Free Cash Flow to Equity Current share price of US$11.37 suggests Certara is potentially 27% overvalued Analyst price target for ...

Certara, Inc. reports Q1 2025 revenue of $106 million, a 10% increase, with net income of $4.7 million. Certara, Inc. reported strong financial results for the first quarter of fiscal 2025 ...

Certara is well positioned to support the continued adoption of Biosimulation by industry to gain important insights into new therapies. We continue to work closely with our customers as they ...

Certara reaffirmed its revenue guidance for 2025, projecting $415 million to $425 million, representing an 8% to 10% growth. Adjusted EBITDA margins are expected to range between 30% and 32%.

Q1 2025 Results Conference Call May 5, 2025 5:00 PM ETCompany ParticipantsDavid Deuchler - Investor Relations, Gilmartin ...

Key Insights The projected fair value for Certara is US$8.98 based on 2 Stage Free Cash Flow to Equity Current ...